You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS<br />
Sales of Key Prod ucts for years end ing De cem ber 31:<br />
Unit: $ mil lions<br />
2008 2007 2006 2005 2004<br />
Diovan/Co-Diovan 5,740 5,012 4,223 3,676 3,093<br />
Gleevec/Glivec 3,670 3,050 2,554 2,170 1,634<br />
Zometa 1,382 1,297 1,283 1,224 1,078<br />
Femara 1,129 937 719 536 386<br />
Sandostatin (group) 1,123 1,027 915 896 827<br />
Neoral/Sandimmun 956 944 918 953 1,011<br />
Lucentis 886 393 — — —<br />
Exelon 815 632 525 467 422<br />
Voltaren (group) 814 747 690 689 638<br />
Lescol 645 665 725 767 758<br />
Exjade (group) 531 357 143 — —<br />
Comtan/Stalevo (group) 502 420 339 278 —<br />
Tegretol (incl. CR/XR) 451 413 391 393 396<br />
Ritalin/Focalin (group) 440 375 330 — —<br />
Exforge 406 — — — —<br />
Foradil 387 362 331 332 321<br />
Lotrel 386 748 1,352 1,075 920<br />
Trileptal 332 692 721 615 518<br />
Tobramycin 295 273 177 — —<br />
Myfortic 290 — — — —<br />
Source: Novartis Jan u ary 2009/Novartis An nual Re ports<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 109
Change language